November 2009, Volume 39 Number 11 , p 14 - 14
A report published in the British Medical Journal indicates that heart failure and mortality risks are lower in patients taking pioglitazone than in those taking rosiglitazone. Data were collected on 39,736 patients age 66 or older with type 2 diabetes who were started on rosiglitazone or pioglitazone. During a 72-month period, the risks of death and heart failure for those taking pioglitazone were 14% and 23% lower, respectively, than with rosiglitazone.
Because rosiglitazone has no clear clinical advantage over pioglitazone, continuing to prescribe it may not be worth the risks.
Source: de Vries CS, Russell-Jones DL. Rosiglitazone or pioglitazone in type 2 diabetes? BMJ . 2009;339:b3076.
PAIN MEDICATIONS Ibuprofen best for arm fractures in kids
Studying the effects of ibuprofen on postfracture pain in children, ...